Search results
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 1 day agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
Is This a Setback for Moderna?
The Motley Fool via AOL· 2 days agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
Adult RSV Shots Given to More Than 30 Babies by Mistake
MedPage Today· 7 days agoNearly three dozen babies and young children have received respiratory syncytial virus (RSV)...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 2 days agoShares of Moderna, Inc. MRNA were down 4.4% on May 10 after the company announced that the FDA has...
NanoViricides unveils new data showing lead drug asset’s strong activity against RSV
Proactive Investors· 2 days agoNanoViricides (NYSE-A:NNVC) has released new data which shows the strength of the antiviral activity...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Digital Journal· 2 days ago(NYSE Amer.:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have ...
FDA Delays Decision on Moderna RSV Shot by 3 Weeks
Barrons.com· 6 days agoThe agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the drug’s safety, efficacy, or...
Moderna says FDA delayed RSV vaccine approval to end of May
CNBC· 6 days agoThe FDA was expected to make a decision on the RSV shot on Sunday. The agency has not informed...
Moderna's RSV Vaccine Approval Faces Setback as FDA Delays Decision
Homenewshere.com· 5 days agoModerna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to...
US FDA pushes decision on Moderna's RSV vaccine to end of this month
Reuters via AOL· 6 days agoModerna's shares fell 3% to $119.02 in early trading. The Food and Drug Administration's move...